{
    "xml": "<topic id=\"PHP4062\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/insulin-glulisine\" basename=\"insulin-glulisine\" title=\"INSULIN GLULISINE\">\n<title>INSULIN GLULISINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_265\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/insulin\">Insulin</xref>\n</p>\n<data name=\"vtmid\">411532008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_654406860\" title=\"Insulins\">Insulins</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34635\" title=\"INSULINS\" namespace=\"/drug-classes/insulins\">INSULINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">Recombinant human insulin analogue</p>\r\n</body>\n<topic id=\"PHP72146\" outputclass=\"indicationsAndDose\" rev=\"1.35\" parent=\"/drugs/insulin-glulisine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Diabetes mellitus</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child</p>\n<p>Administer immediately before meals or when necessary shortly after meals, according to requirements.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Administer immediately before meals or when necessary shortly after meals, according to requirements.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By subcutaneous infusion or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child</p>\n<p>According to requirements.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>According to requirements.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71193\" outputclass=\"unlicensedUse\" rev=\"1.7\" parent=\"/drugs/insulin-glulisine\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Not licensed for children under 6 years.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71988\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/insulin-glulisine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (antidiabetics).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68135\" outputclass=\"directionsForAdministration\" rev=\"1.10\" parent=\"/drugs/insulin-glulisine\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in adults</p>\n<p>For <i>intravenous infusion </i> (<i>Apidra</i>\n<tm tmtype=\"reg\"/>), give continuously in Sodium chloride 0.9%; dilute to 1&#8239;unit/mL with infusion fluid; use a co-extruded polyolefin/polyamide plastic infusion bag with a dedicated infusion line.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71107\" outputclass=\"nationalFunding\" rev=\"1.17\" parent=\"/drugs/insulin-glulisine\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA151</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008)</p>\r\n<p>Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes: </p>\r\n<ul>\r\n<li>who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, <b>or</b>\r\n</li>\r\n<li>whose glycaemic control remains inadequate (HbA<sub>1c</sub> over 8.5% [69&#8239;mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).</li>\r\n</ul>\r\n<p>Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA151\">www.nice.org.uk/TA151</xref>\n</sectiondiv>\n</sectiondiv>\r\n<sectiondiv outputclass=\"smcDecisions\">\r\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\r\n<sectiondiv outputclass=\"smcDecision\">\r\n<sectiondiv>\r\n<p>The <i>Scottish Medicines Consortium</i> has advised (October 2008) that <i>Apidra</i>\r\n<tm tmtype=\"reg\"/> is accepted for restricted use within NHS Scotland for the treatment of adults and children over 6 years with diabetes mellitus in whom the use of a short-acting insulin analogue is appropriate.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP4062-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/insulin-glulisine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76323\" title=\"Solution for injection\" namespace=\"/drugs/insulin-glulisine/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78107\" namespace=\"/treatment-summaries/insulins-and-anti-diabetic-drugs\" title=\"Insulins and anti-diabetic drugs\" count=\"2\" rel=\"backlink\">Insulins and anti-diabetic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_265\" namespace=\"/interactions/list-of-drug-interactions/antidiabetics/insulin\" title=\"Insulin\" count=\"1\" rel=\"link\">Insulin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34635\" namespace=\"/drug-classes/insulins\" title=\"INSULINS\" count=\"1\" rel=\"link\">INSULINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76323\" namespace=\"/drugs/insulin-glulisine/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP4062",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/insulin-glulisine",
    "basename": "insulin-glulisine",
    "title": "INSULIN GLULISINE",
    "interactants": [
        {
            "id": "bnf_int_265",
            "label": "Insulin"
        }
    ],
    "vtmid": "411532008",
    "drugClassification": [
        "Insulins"
    ],
    "inheritsFromClass": [
        "INSULINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Recombinant human insulin analogue"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Diabetes mellitus",
                        "html": "Diabetes mellitus"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous infusion or intravenous infusion"
                    ],
                    "textContent": "By subcutaneous infusion or by intravenous infusion",
                    "html": "By subcutaneous infusion or by intravenous infusion"
                },
                "child": [
                    {
                        "textContent": "Administer immediately before meals or when necessary shortly after meals, according to requirements.",
                        "html": "<p>Administer immediately before meals or when necessary shortly after meals, according to requirements.</p>"
                    },
                    {
                        "textContent": "According to requirements.",
                        "html": "<p>According to requirements.</p>"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Administer immediately before meals or when necessary shortly after meals, according to requirements.",
                        "html": "<p>Administer immediately before meals or when necessary shortly after meals, according to requirements.</p>"
                    },
                    {
                        "textContent": "According to requirements.",
                        "html": "<p>According to requirements.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Not licensed for children under 6 years.",
                "html": "<p>Not licensed for children under 6 years.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (antidiabetics).",
                "html": "<p>Appendix 1 (antidiabetics).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.",
                "html": "<p>Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in adults",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Apidra ), give continuously in Sodium chloride 0.9%; dilute to 1 unit/mL with infusion fluid; use a co-extruded polyolefin/polyamide plastic infusion bag with a dedicated infusion line.",
                "html": "<p>For <i>intravenous infusion </i> (<i>Apidra</i>\n<tm tmtype=\"reg\"/>), give continuously in Sodium chloride 0.9%; dilute to 1&#8239;unit/mL with infusion fluid; use a co-extruded polyolefin/polyamide plastic infusion bag with a dedicated infusion line.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA151",
                        "label": "www.nice.org.uk/TA151"
                    }
                ],
                "fundingIdentifier": "NICE TA151",
                "textContent": "Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008) Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes: who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or whose glycaemic control remains inadequate (HbA1c over 8.5% [69 mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate). Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years.\n\nwww.nice.org.uk/TA151",
                "html": "<p outputclass=\"title\">Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008)</p> <p>Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes: </p> <ul> <li>who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, <b>or</b> </li> <li>whose glycaemic control remains inadequate (HbA<sub>1c</sub> over 8.5% [69&#8239;mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).</li> </ul> <p>Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA151\">www.nice.org.uk/TA151</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76323",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78107",
                "label": "Insulins and anti-diabetic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_265",
                "label": "Insulin",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34635",
                "label": "INSULINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76323",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}